Search
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalUse (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigationalL46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057] As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnCyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigationalPirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneum...
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedInvestigationalGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnTriflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of n...